<DOC>
	<DOCNO>NCT00081601</DOCNO>
	<brief_summary>The purpose study determine proportion patient serological prostate specific antigen ( PSA ) day 85 .</brief_summary>
	<brief_title>Study CEP-701 Treatment Prostate Cancer</brief_title>
	<detailed_description>A serological PSA response define reduction baseline PSA serum concentration least 50 % , confirm second PSA value 28 day later .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>least 18 yrs age diagnosis adenocarcinoma prostate detectable metastatic disease assess bone CT scan increase serum PSA concentration life expectancy least 3 month ECOG 0 1 withdrawn antiandrogen therapy least 6 week prior enter screen period asymptomatic disease active GI ulceration bleed treat nonhormonal systemic anticancer therapy receive radiation within 4 week baseline visit bilirubin &gt; 2x ULN ALT AST &gt; 2xULN serum creatinine &gt; 1.5mg/dL hemoglobin &lt; 9g/dL platelet 100,000/uL ANC 1500/uL receive treatment HIV protease inhibitor prior malignancy within past 5 yr exception resect basal squamous cell carcinoma skin use investigational drug previous one month</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>prostate specific antigen</keyword>
	<keyword>PSA</keyword>
</DOC>